<DOC>
	<DOCNO>NCT00942435</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety oral dose YM150 prevention venous thromboembolism ( VTE ) patient undergo major abdominal surgery .</brief_summary>
	<brief_title>A Study Assess Effect YM150 Prevention Venous Thromboembolism Patients Undergoing Major Abdominal Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<criteria>Patients major abdominal surgery Written inform consent obtain Subject history symptomatic deep vein thrombosis and/or pulmonary embolism Subject hemorrhagic disorder and/or coagulation disorder Subject clinically important bleeding occur within 90 day prior screen visit Subject active bacterial endocarditis Subject uncontrolled severe moderate hypertension , retinopathy , myocardial infarction stroke Subject receive anticoagulants/antiplatelet agent Subject thrombocytopenia Body weight less 40 kg screening</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>YM150</keyword>
	<keyword>Bleeding</keyword>
	<keyword>VTE</keyword>
	<keyword>FXa inhibitor</keyword>
	<keyword>Deep Vein Thrombosis</keyword>
	<keyword>Venous thromboembolism</keyword>
</DOC>